Thyroid Cancer Treatment Market 2025 | Latest FDA Approvals, M&A Deals & Research Updates, Clinical Phases - Key Industry Players are Genentech USA, Inc, Blueprint Medicines Corporation, Daiichi Sankyo, Inc., BeiGene, Ltd, Taiho Oncology, Inc

thyroid cancer treatment market size reached US$ 1.14 billion in 2024 and is expected to reach US$ 2.94 billion by 2033, growing at a CAGR of 11.2% during the forecast period 2025-2033.

DataM Intelligence has published a new research report on "Thyroid Cancer Treatment Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

New Product Launches & Clinical Trials

Several promising drugs in Phase 2/3 trials include zanzalintinib (tyrosine kinase inhibitor) combined with cemiplimab (immunotherapy) for BRAF wildtype anaplastic thyroid cancer designed to increase resectability and survival.​

Larotrectinib, targeting NTRK fusion-positive thyroid cancer, shows near 90% tumor shrinkage in first-line treatment studies, providing an alternative to chemotherapy with fewer side effects.​

Clinical trials are ongoing for RET inhibitors, BRAF/MEK inhibitors, and novel TKIs addressing radioiodine refractory thyroid cancers and those with genetic mutations

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/thyroid-cancer-treatment-market?kb

Latest M&A Activity

In early 2025, GSK acquired IDRx for $1.15 billion, gaining access to IDRx-42, a selective tyrosine kinase inhibitor (TKI) designed to address resistance mutations in solid tumors including thyroid cancer.​

Eli Lilly acquired Scorpion Therapeutics in Q1 2025 for up to $2.5 billion, adding precision oncology candidates that could extend into thyroid cancer indications.​

Lantheus Holdings completed a $250 million acquisition of Evergreen Theragnostics to strengthen radiopharmaceutical supply for thyroid cancer imaging and treatment.​

ESTEVE acquired rights to Caprelsa® (vandetanib), a kinase inhibitor for medullary thyroid cancer, from Sanofi in more than 50 countries, expanding their rare disease portfolio.

Key Players:

Merck & Co., Inc., Eli Lilly and Company, Genentech USA, Inc., Pfizer Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Blueprint Medicines Corporation, Daiichi Sankyo, Inc., BeiGene, Ltd., Ipsen Biopharmaceuticals Inc., Taiho Oncology, Inc., and Deciphera Pharmaceuticals, LLC

Recent FDA Approvals

In March 2025, Exelixis' CABOMETYX (cabozantinib) received FDA approval for treating advanced neuroendocrine tumors including thyroid cancers harboring specific mutations.​

The FDA approved the combination of LENVIMA (lenvatinib) with KEYTRUDA (pembrolizumab) in October 2025, showing durable 5-year survival benefits in advanced thyroid cancer cases.​

Continued approvals of new targeted therapies and radiopharmaceuticals are enhancing treatment options for differentiated, medullary, and anaplastic thyroid cancers

Growth Forecast Projected:

The Global Thyroid Cancer Treatment Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Thyroid Cancer Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=thyroid-cancer-treatment-market?kb

Key Segments:

By Cancer Type: Papillary Thyroid Cancer, Follicular Thyroid Cancer, Oncocytic Cell (Hurthle Cell) Thyroid Cancer, Medullary Thyroid Cancer, Anaplastic Thyroid Cancer

By Treatment Type: Radioactive Iodine Therapy, Radiation Therapy, Chemotherapy, Dacarbazine, Doxorubicin, Streptozocin, 5-Fluorouracil, Paclitaxel, Docetaxel, Cisplatin, Carboplatin, Others, Targeted Therapy, TRK Inhibitors, RET Inhibitors, BRAF and MEK Inhibitors, Multikinase Inhibitors, Others, Hormone Therapy, Surgery, Others

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Thyroid Cancer Treatment producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Thyroid Cancer Treatment revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/thyroid-cancer-treatment-market?kb

FAQ's

Q: How fast is the Thyroid Cancer Treatment Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 11.2% from 2025 to 2032

Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/thyroid-cancer-treatment-market?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.